Affiliation: Washington University School of Medicine
- The impact of ethnicity on hepatitis C virus treatment decisions and outcomesMauricio Lisker-Melman
Hepatology Program, Division of Gastroenterology, Washington University School of Medicine, St Louis, MO 63110 1010, USA
Dig Dis Sci 58:621-9. 2013....
- Defining optimal therapeutic outcomes in chronic hepatitisMauricio Lisker-Melman
Division of Gastroenterology, Hepatology Program, Washington University School of Medicine, St Louis, Missouri 63110 1010, USA
Arch Med Res 38:652-60. 2007..Now that clearer therapeutic outcomes have been refined, more efficacious, and better-tolerated drugs may change the current therapeutic landscape of chronic viral hepatitis B and C...
- Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinomaDaniel B Brown
Mallinckrodt Institute of Radiology, Siteman Cancer Center, Washington University Medical Center, 510 South Kingshighway Boulevard, St Louis, Missouri 63110, USA
J Vasc Interv Radiol 15:1209-18. 2004..To compare the value of the Child-Pugh and Model for End-stage Liver Disease (MELD) scores to predict patient survival rates after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC)...
- Liver transplant for hepatitis C virus: effect of using older donor grafts on short- and medium-term survivalM B Majella Doyle
Department of Surgery, Section of Abdominal Transplantation, Washington University School of Medicine, St Louis, Missouri 63110, USA
Arch Surg 143:679-85; discussion 685. 2008..In addition, recent studies suggest that the use of older donors in recipients with HCV is associated with significantly worsened short- and long-term survival...
- Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virusMaria Ristig
Division of Infectious Diseases, Hepatology Program, Washington University School of Medicine, St Louis, Missouri, USA
AIDS Patient Care STDS 17:439-42. 2003..The patient was subsequently removed from the liver transplant program and has not suffered from any further hepatic complications...
- Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infectionJayaprakash Sreenarasimhaiah
Department of Gastroenterology, Washington University School of Medicine, St Louis, MO 63110, USA
Hum Immunol 64:497-504. 2003..These results indicate that enhancement of HCV-specific CD4(+) and CD8(+) T-cell responses is an important factor in determining the response to the IFN-alpha/ribavirin therapy and the outcome of the HCV infection...
- Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trialSurendra Shenoy
The Department of Surgery, Washington University, St Louis, MO 63110, USA
Transplantation 83:1389-92. 2007..Although early improvements were observed, withdrawing CNI and replacing it with SRL did not result in a statistically significant improvement in renal function at 12 months of follow-up...
- Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosisAnkit Bharat
Department of Surgery, Washington University School of Medicine, St Louis, MO 63110, USA
Transplantation 84:1704-7. 2007..Further, sCD30 may represent a novel marker for surveillance of hepatic cirrhosis in transplant recipients with chronic HCV infection...
- Immune response to extracellular matrix collagen in chronic hepatitis C-induced liver fibrosisBrian B Borg
Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
Liver Transpl 17:814-23. 2011..Our results demonstrate that in HCV-infected patients, the levels of Abs to ECM Col1, Col2, and Col5 positively correlate with liver fibrosis, which is associated with a predominantly T(h) 2 and T(h) 17 cytokine profile...
- Liver volume in the cirrhotic patient: does size matter?Michael T Hagan
Division of Gastroenterology, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid, Campus Box 8124, St Louis, MO, USA
Dig Dis Sci 59:886-91. 2014..While it is established that cirrhosis results in a decrease in liver volume (LV), whether LV itself predicts patient survival is unknown. We hypothesize that estimated LV is an important prognostic indicator in patients with cirrhosis...
- A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipientsSurendra Shenoy
Department of Medicine, Washington University, Barnes Jewish Hospital, St Louis, MO 63110, USA
Liver Transpl 14:173-80. 2008..In conclusion, immunosuppression with CsA, monitored by C2 levels, is safe, effective, and economical in liver transplant recipients and provides immunosuppression at least equivalent to that of FK...
- Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agentsDaniel B Brown
Mallinckrodt Institute of Radiology, Washington University Medical Center, 510 South Kingshighway Boulevard, St Louis, Missouri 63110, USA
J Vasc Interv Radiol 16:1661-6. 2005..The optimal embolic agent for transhepatic arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) has not been identified. This study reports outcomes of TACE for HCC with Gelfoam powder and polyvinyl alcohol (PVA)...
- Treatment of chronic hepatitis B: are we ready for combination therapy?Anil Seetharam
Division of Gastroenterology, Washington University in St Louis, 660 South Euclid Avenue, St Louis, MO 63110, USA
Curr Gastroenterol Rep 11:22-7. 2009..Although combination therapy has proven successful in chronic hepatotropic viral infections and in chronic, noninfectious medical conditions, its benefits must be weighed against risks such as increased toxicity, resistance, and cost...
- Advanced donor age alone does not affect patient or graft survival after liver transplantationChristopher D Anderson
Department of Surgery, Section of Abdominal Transplantation, Washington University School of Medicine, St Louis, MO, USA
J Am Coll Surg 207:847-52. 2008..We hypothesized that proper selection of donors older than age 60 would not disadvantage recipients in terms of patient and graft survival...
- Lack of optimal T-cell reactivity against the hepatitis C virus is associated with the development of fibrosis/cirrhosis during chronic hepatitisJayaprakash Sreenarasimhaiah
Department of Gastroenterology, Washington University School of Medicine, St Louis, Missouri 63110, USA
Hum Immunol 64:224-30. 2003..These results indicate that a lack of an optimal T-cell response to HCV is associated with the development of cirrhosis during chronic HCV infection...
- Liver transplantation for hepatocellular carcinoma: expanding special priority to include stage III diseaseJeremy Goodman
Section of Abdominal Transplantation, Department of Surgery, Washington University, St Louis, MO, USA
Arch Surg 140:459-64; discussion 464. 2005..After liver transplantation, patients with stage III hepatocellular carcinoma (HCC) experience survivals similar to those of patients with less advanced disease and of matched control subjects...
- The use of psychoeducation for a patient with hepatitis C and psychiatric illness in preparation for antiviral therapy: a case report and discussionBarry A Hong
Department of Psychiatry, Washington University, School of Medicine, 660 S Euclid Avenue, Campus Box 8134, St Louis, MO 63110, USA
J Clin Psychol Med Settings 18:99-107. 2011..The challenge is to help patients overcome barriers to treatment, particularly psychosocial problems, because available treatments are increasingly effective...
- Bone marrow biopsy in patients with hepatitis C virus infection: spectrum of findings and diagnostic utilityJeffery M Klco
Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri 63110, USA
Am J Hematol 85:106-10. 2010....
- Hepatic glycogenosis: an underrecognized source of abnormal liver function tests?Gregory S Sayuk
Division of Gastroenterology, Washington University School of Medicine, 660 South Euclid Avenue, Saint Louis, MO 63110, USA
Dig Dis Sci 52:936-8. 2007
- Disseminated histoplasmosis in a liver transplant recipientYoung S Oh
Division of Gastroenterology, Washington University School of Medicine, St Louis, MO, USA
Liver Transpl 12:677-81. 2006..Histoplasmosis should be considered in liver transplant patients with diarrhea and large ulcers in the colon. The presence of disseminated histoplasmosis should be ruled out once colonic histoplasmosis has been diagnosed...
- Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failedMaria B Ristig
Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri 63108, USA
J Infect Dis 186:1844-7. 2002..There was a transient increase of transaminases after the initiation of treatment. No patient developed HBe antibodies. TDF is a very promising drug for the treatment of chronic hepatitis B in HIV-infected individuals...